Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival.

As tumors maintain an inflammatory microenvironment, anti-inflammatory medication can be useful in cancer therapy. We have previously shown an association with improved survival in melanoma for use of the H₁-antihistamines desloratadine and loratadine, and here we examine use of H₁-antihistamines and breast cancer mortality. We investigated use of the six major H₁-antihistamines (cetirizine, clemastine, desloratadine, ebastine, fexofenadine and loratadine) and breast cancer-specific and overall mortality in a nation-wide register-based study of all 61,627 Swedish women diagnosed with breast cancer 2006–2013. Both peri- and post-diagnostic antihistamine use was analyzed using Cox regression models. Analyses were stratified for age and subgroup analyses based on estrogen receptor status and menopausal status were performed. We found a consistently improved survival of desloratadine users (HR = 0.67; 95% CI 0.55–0.81, p <.001), as well as of loratadine users (HR = 0.80; 95% CI 0.67–0.95, p =.012), relative to nonusers, regardless of patient age, menopause, estrogen receptor status or stage of the tumor, or whether breast cancer-specific or overall survival was analyzed. The survival of users of other antihistamines varied relative to non-users. Based on their safety and current use within the patient population, together with our observations, we suggest the initiation of trials of desloratadine and loratadine as treatment of breast cancer as well as studies of the mechanism behind their possible effect. Further studies on any effects of other H₁-antihistamines may also be merited, as well as of H₁-antihistamine use and survival in other malignancies. [ABSTRACT FROM AUTHOR]